FTC Renews Challenge of More Than 200 Improper Patent Listings
May 21, 2025
May 21, 2025
WASHINGTON, May 21 -- The Federal Trade Commission issued the following news release:
* * *
FTC Renews Challenge of More Than 200 Improper Patent Listings
Continuing its efforts to promote competition and lower drug prices, today the Federal Trade Commission renewed its challenges against dozens of improperly listed device patents that shield brand-name asthma, diabetes, epinephrine autoinjector, and COPD drugs from prompt generic competition.
. . .
* * *
FTC Renews Challenge of More Than 200 Improper Patent Listings
Continuing its efforts to promote competition and lower drug prices, today the Federal Trade Commission renewed its challenges against dozens of improperly listed device patents that shield brand-name asthma, diabetes, epinephrine autoinjector, and COPD drugs from prompt generic competition.
. . .